Orris

Prolonged meropenam infusion v/s intermittent bolus in neonatal sepsis

Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"meropenem" AND "extended infusion" AND neonat*

Searching PubMed

carbapenem prolonged infusion sepsis pharmacokinetics

Searching the Web

prolonged infusion vs intermittent bolus meropenem neonatal sepsis trial

Reading Article

PMID: 27918382

Reading Article

PMID: 22733063

Reading Article

PMID: 35326804

Reading Article

PMID: 40693969

Reading File

Prolonged (Extended) Infusion vs Intermittent Bolus Meropenem in Neonatal Sepsis

The pharmacologic rationale

Meropenem is a time-dependent antibiotic — efficacy correlates with the percentage of the dosing interval that free drug concentration stays above the MIC (%fT>MIC), not peak concentration. Giving the same total dose over a longer infusion (2-4 h "extended/prolonged infusion") instead of a 30-min bolus raises %fT>MIC, especially against organisms with higher MICs (e.g., Pseudomonas, resistant Gram-negatives) — which is the main justification for using it in neonatal Gram-negative sepsis (Meropenem monograph - The Harriet Lane Handbook, 23rd ed., p. 1230; standard neonatal dosing 20-40 mg/kg/dose q8-12h by weight/age band).

Clinical evidence in neonates

1. Shabaan et al. 2017 (RCT, Mansoura, Egypt) — PMID 27918382 This is the key neonatal RCT. 102 neonates with Gram-negative late-onset sepsis randomized to meropenem infused over 4 hours vs 30 minutes (same dose/interval).
  • Clinical improvement and microbiologic eradication at day 7: significantly higher with prolonged infusion
  • Mortality: significantly lower with prolonged infusion
  • Duration of respiratory support: significantly shorter with prolonged infusion
  • Acute kidney injury: significantly less with prolonged infusion
  • Conclusion: prolonged infusion was superior on every measured outcome with no safety penalty.
2. Cao et al. 2022 (historical cohort, China) — PMID 35326804 256 neonates with sepsis, extended infusion (2-3h) vs standard (0.5h).
  • 3-day clinical effectiveness and 3-day microbial clearance: significantly better with extended infusion
  • Very-low-birth-weight neonates benefited most (75.6% vs 56.6% effectiveness)
  • No difference between 2h and 3h infusion durations
  • Safety comparable, but authors flag that a historical/observational design carries bias risk and called for confirmatory RCTs.
3. Padari et al. 2012 (PK study, VLBW neonates) — PMID 22733063 A pharmacokinetic (not outcome) study in very-low-birth-weight neonates comparing 30-min vs 4-h infusions at 20 mg/kg q12h.
  • Short infusion gave a much higher Cmax (89 vs 54 mg/L) but in nearly all patients (both groups) free drug stayed above the target MIC (2 mg/L) 100% of the interval regardless of infusion length
  • Conclusion: in this population, a 30-min infusion was pharmacokinetically "acceptable," and dosing did not need adjustment in the first month of life — i.e., PK alone did not mandate prolonged infusion for organisms with low MICs, though it doesn't contradict the clinical benefit seen against higher-MIC pathogens.
4. A more recent real-world study (2025) — PMID 40094943 ("Are Three Hours Long Enough?") raises the question of whether even 3-hour infusions achieve adequate PK targets in critically ill neonates/children, suggesting infusion duration optimization is still evolving.

Supporting evidence from adult/mixed sepsis meta-analyses (extrapolated, not neonate-specific)

  • Qiu et al. 2025 meta-analysis (18 studies, 3703 patients, mixed populations) — PMID 40693969: prolonged infusion reduced mortality (RR 0.85, 95% CI 0.76-0.95), improved clinical cure (RR 1.35) and microbiological eradication (RR 1.13) vs short infusion.
  • Abdul-Aziz et al. 2024 JAMA meta-analysis (adults) — PMID 38864162: prolonged/continuous beta-lactam infusion associated with lower mortality in critically ill sepsis/septic shock patients.
  • A 2025 meta-analysis specific to meropenem (Mu et al., PMID 39864658) similarly found lower mortality with prolonged infusion (RR 0.81, 95% CI 0.68-0.98).
  • Note: not all meta-analyses agree — one 2025 systematic review restricted to continuous infusion RCTs in critically ill adults (PMID 40557041) found no significant mortality benefit for continuous infusion specifically, though it did show shorter ICU stay and higher clinical cure. This reflects heterogeneity between "prolonged" (2-4h) and "continuous" (24h) infusion strategies and patient populations — findings from adults should be extrapolated to neonates cautiously.

Bottom line for neonatal sepsis

The direct neonatal evidence (one RCT plus one cohort study) consistently favors prolonged infusion (2-4 hours) over conventional 30-minute bolus for meropenem in neonates with Gram-negative sepsis, showing better clinical/microbiologic response and, in the RCT, lower mortality and less nephrotoxicity — with no demonstrated safety disadvantage. This is biologically consistent with meropenem's time-dependent PK/PD profile, particularly relevant for higher-MIC organisms and preterm/VLBW infants who have altered renal clearance and larger volumes of distribution. However, the neonatal evidence base is still small (essentially one RCT of 102 patients and one 256-patient cohort), so guidelines have not universally mandated prolonged infusion, and optimal infusion duration (2h vs 3h vs 4h) remains under study.
Evidence gap flag: No large multicenter neonatal RCT has been published confirming the mortality benefit seen in the single Egyptian RCT; adult BLING III-type trial data (mentioned in a 2024 meta-analysis) may eventually clarify this further but doesn't directly include neonates. Treat the mortality-benefit claim in neonates as promising but based on limited trial data, not yet a firm practice standard.
This is a shared conversation. Sign in to Orris to start your own chat.